Efficacy of Pregabalin in the Management of Cetuximab-Related Itch

Journal of Pain and Symptom Management

Volumn 32, Issue 5, 2006, Pages 397-398

  Porzio, Giampiero ^a   Aielli, Federica ^a   Verna, Lucilla ^a   Porto, Claudio ^b   Tudini, Marianna ^a   Cannita, Katia ^a   Ficorella, Corrado ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAN SALVATORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; CETUXIMAB; GABAPENTIN; PREGABALIN; PROMETHAZINE;

ACNE; ANXIETY DISORDER; ASTHENIA; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DROWSINESS; DRY SKIN; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LUNG EMBOLISM; NOSE CANCER; PRURITUS; RATING SCALE; SLEEP DEPRIVATION;

ANALGESICS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PRURITUS; TREATMENT OUTCOME;

EID: 33750502032     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2006.07.006     Document Type: Letter

References (10)

1. Segaert S., and Can Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16 (2005) 1425-1433
2. Segaert S., Tabernero J., Chosidow O., et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 3 (2005) 599-606
3. Lacouture M.E., Basti S., Patel J., and Benson III A. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 4 5 (2006) 236-238
4. Perez-Soler R., Delord J.P., Halpern A., et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10 (2005) 345-356
5. Scheinfeld N. The role of gabapentin in treating disease with cutaneous manifestations. Int J Dermatol 42 (2003) 491-495
6. Winhoven S.M., Coulson I.H., and Bottomley W.W. Brachioradial pruritus: response to treatment with gabapentin. Br J Dermatol 150 (2004) 786-787
7. Yesudian P.D., and Wilson N.J.E. Efficacy of gabapentin in the management of pruritus of unknown origin. Arch Dermatol 141 (2005) 1507-1509
8. Fehrenbacher J.C., Taylor C.P., and Vasko M.R. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 105 (2003) 133-141
9. Yoon M.H., Choi J., and Jeong S.W. Spinal gabapentin and antinociception: mechanisms of action. J Korean Med Sci 18 (2003) 255-261
10. Shneker B.F., and McAuley J.W. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 39 (2005) 2029-2037